Combining osimertinib with chemotherapy significantly improved overall survival in advanced EGFR-mutated non-small cell lung cancer. The FLAURA2 trial showed a consistent survival benefit and extended ...
Cisplatin-based NAC and AMVAC improved two-year MFS in MIBC patients, with a 72.9% overall MFS rate. 17% of all patients and 48% in the AS group avoided cystectomy without metastatic disease. Severe ...
Urinary tract infections (UTIs) commonly occur in people who undergo chemotherapy. The treatment can weaken the immune system and damage barriers, such as the skin and mucous membranes, that help ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results